UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

[X]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended JuneSeptember 30, 2019

 

OR

 

[  ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 001-38015

 

Sigma Labs, Inc.

(Exact name of registrant as specified in its charter)

 

NEVADA 27-1865814

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

3900 Paseo del Sol

Santa Fe, NM 87507

(Address of principal executive offices)

 

(505) 438-2576

(Registrant’s telephone number)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol Name of each exchange on which registered
Common Stock, par value $0.001 per share SGLB The NASDAQ Stock Market LLC

Warrants to Purchase Common Stock,

par value $0.001 per share

 SGLBW The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No[  ]

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer[  ]Accelerated Filer[  ]
Non-accelerated filer[  ]Smaller reporting company[X]
Emerging growth company[  ]  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.[  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes[  ]No [X]

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: As of AugustNovember 14, 2019, the issuer had 13,812,59014,037,590 shares of common stock outstanding.

 

 

   

 

SIGMA LABS, INC.

 

FORM 10-Q

 

TABLE OF CONTENTS

 

PART I - FINANCIAL INFORMATION3
  
ITEM 1. FINANCIAL STATEMENTS3
  
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS12
  
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK1617
  
ITEM 4. CONTROLS AND PROCEDURES1617
  
PART II - OTHER INFORMATION18
  
ITEM 1. LEGAL PROCEEDINGS1718
  
ITEM 1A. RISK FACTORS1718
  
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.1718
  
ITEM 3. DEFAULTS UPON SENIOR SECURITIES1718
  
ITEM 4. MINE SAFETY DISCLOSURES1718
  
ITEM 5. OTHER INFORMATION1718
  
ITEM 6. EXHIBITS1718
  
SIGNATURES1819

2

PART I. FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS.

 

Sigma Labs, Inc.

Condensed Balance Sheets

(Unaudited)

 

  June 30, 2019  December 31, 2018 
       
ASSETS        
Current Assets:        
Cash $696,390  $1,279,782 
Accounts Receivable, net  37,982   38,800 
Note Receivable  79,875   121,913 
Inventory  570,426   240,086 
Prepaid Assets  68,718   67,255 
Total Current Assets  1,453,391   1,747,836 
         
Other Assets:        
Property and Equipment, net  205,538   277,944 
Intangible Assets, net  510,718   404,978 
Investment in Joint Venture  500   500 
Total Other Assets  716,756   683,422 
         
TOTAL ASSETS $2,170,147  $2,431,258 
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
         
Current Liabilities:        
Accounts Payable $368,055  $217,488 
Notes Payable  50,000   50,000 
Deferred Revenue  78,773   51,498 
Accrued Expenses  271,154   376,833 
Total Current Liabilities  767,982   695,819 
         
TOTAL LIABILITIES  767,982   695,819 
         
Commitments & Contingencies        
         
Stockholders’ Equity        
Preferred Stock, $0.001 par; 10,000,000 shares authorized; None issued and outstanding, respectively  -   - 
Common Stock, $0.001 par; 22,500,000 shares authorized; 10,937,590, and 8,776,629 issued and outstanding, respectively  10,938   8,777 
Additional Paid-In Capital  24,243,575   21,501,407 
Accumulated Deficit  (22,852,348)  (19,774,745)
Total Stockholders’ Equity  1,402,165   1,735,439 
         
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $2,170,147  $2,431,258 

  September 30, 2019  December 31, 2018 
       
ASSETS        
Current Assets:        
Cash $1,111,430  $1,279,782 
Accounts Receivable, net  81,203   38,800 
Note Receivable  -   121,913 
Inventory  712,587   240,086 
Prepaid Assets  246,446   67,255 
Total Current Assets  2,151,666   1,747,836 
         
Other Assets:        
Property and Equipment, net  164,962   277,944 
Intangible Assets, net  559,147   404,978 
Investment in Joint Venture  500   500 
Total Other Assets  724,609   683,422 
         
TOTAL ASSETS $2,876,275  $2,431,258 
         
LIABILITIES AND STOCKHOLDERS’ EQUITY        
         
Current Liabilities:        
Accounts Payable $423,059  $217,488 
Notes Payable  50,000   50,000 
Deferred Revenue  99,843   51,498 
Accrued Expenses  199,338   376,833 
Total Current Liabilities  772,240   695,819 
         
TOTAL LIABILITIES  772,240   695,819 
         
Commitments & Contingencies        
         
Stockholders’ Equity        
Preferred Stock, $0.001 par; 10,000,000 shares authorized; None issued and outstanding, respectively  -   - 
Common Stock, $0.001 par; 22,500,000 shares authorized; 14,037,590, and 8,776,629 issued and outstanding, respectively  14,038   8,777 
Additional Paid-In Capital  26,543,139   21,501,407 
Accumulated Deficit  (24,453,142)  (19,774,745)
Total Stockholders’ Equity  2,104,035   1,735,439 
         
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $2,876,275  $2,431,258 

 

See accompanying notes to condensed financial statements.

3

Sigma Labs, Inc.

Condensed Statements of Operations

(Unaudited)

 

 

Three Months Ended

June 30,

 

Six Months Ended

June 30,

  

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 
 2019  2018  2019  2018  2019 2018 2019 2018 
                  
REVENUES $33,582  $98,663  $98,032  $202,078  $171,003  $128,593  $269,035  $330,671 
                                
COST OF REVENUE  60,625   68,568   157,180   142,363   

178,760

   56,309   335,939   198,672 
                                
GROSS PROFIT  (27,043)  30,095   (59,148)  59,715 
GROSS PROFIT (LOSS)  

(7,757

)  72,284   (66,904)  131,999 
                                
OPERATING EXPENSES:                                
Salaries & Benefits  581,356   426,049   1,093,916   824,706   644,800   524,508   1,738,716   1,349,214 
Stock-Based Compensation  220,360   423,067   474,566   584,589   154,202   198,578   628,768   783,167 
Operating R&D Costs  118,845   95,045   264,117   217,022   212,230   139,090   476,346   356,112 
Investor & Public Relations  157,318   103,197   315,107   283,596   194,130   142,821   509,237   426,417 
Legal & Professional Service Fees  218,919   177,929   403,489   316,352   116,221   185,676   519,710   502,028 
Office Expenses  184,068   110,936   350,178   206,042   186,430   131,629   536,608   337,671 
Depreciation & Amortization  49,203   48,253   97,586   95,574   52,636   48,013   150,222   143,587 
Other Operating Expenses  38,994   38,035   77,203   71,760   40,265   30,772   117,470   102,532 
Total Operating Expenses  1,569,064   1,422,511   3,076,162   2,599,641   1,600,914   1,401,087   4,677,077   4,000,728 
                                
LOSS FROM OPERATIONS  (1,596,107)  (1,392,416)  (3,135,310)  (2,539,926)  (1,608,671)  (1,328,803)  (4,743,981)  (3,868,729)
                                
OTHER INCOME (EXPENSE)                                
Interest Income  7,016   3,719   12,798   17,086   4,812   9,862   17,610   26,948 
State Incentives  -   -   51,877   -   -   -   51,877   - 
Exchange Rate Gain (Loss)  (2,264)  1,304   (2,710)  1,304   (549)  (606)  (3,259)  697 
Interest Expense  (2,136)  (1,411)  (4,258)  (1,411)  (2,149)  (1,278)  (6,407)  (2,688)
Other Income  5,763   -   5,763   - 
Loss on Disposal of Assets  -   -   -   (36,733)  -   -   -   (36,733)
Total Other Income (Expense)  2,616   3,612   57,707   (19,754)  7,877   7,978   65,584   (11,776)
                                
LOSS BEFORE PROVISION FOR INCOME TAXES  (1,593,491)  (1,388,804)  (3,077,603)  (2,559,680)  (1,600,794)  (1,320,825)  (4,678,397)  (3,880,505)
                                
Provision for income Taxes  -   -   -   -   -   -   -   - 
                                
Net Loss $(1,593,491) $(1,388,804) $(3,077,603) $(2,559,680) $(1,600,794) $(1,320,825) $(4,678,397) $(3,880,505)
                                
                
Net Loss per Common Share – Basic and Diluted $(0.15) $(0.25) $(0.31) $(0.48) $(0.12) $(0.16) $(0.43) $(0.62)
                                
Weighted Average Number of Shares Outstanding – Basic and Diluted  10,777,590   5,572,015   10,063,806   5,286,362   12,851,601   8,281,338   10,996,271   6,295,658 

 

See accompanying notes to condensed financial statements.

4

Sigma Labs, Inc.

Condensed Statements of Cash Flows

(Unaudited)

 

 Six Months Ended  Nine Months Ended 
 June 30, 2019  June 30, 2018  September 30, 2019  September 30, 2018 
OPERATING ACTIVITIES                
Net Loss $(3,077,603) $(2,559,680) $(4,678,397) $(3,880,505)
Adjustments to reconcile Net Loss to Net Cash used in operating activities:                
Noncash Expenses:                
Depreciation and Amortization  97,586   95,574   150,222   143,587 
Stock Based Compensation  474,150   594,915   628,768   793,492 
Stock Issued for third Party Services  17,110   - 
Loss on Write-off of Asset  -   36,733   -   36,733 
Change in assets and liabilities:                
Accounts Receivable  818   41,028   (42,403)  (7,501)
Interest Receivable  27,038   38,139   1,391   36,154 
Inventory  (330,340)  47,100   (472,501)  (21,280)
Prepaid Assets  (1,463)  (9,613)  (179,191)  (25,486)
Accounts Payable  150,567   187,495   205,571   169,520 
Deferred Revenue  27,275   34,026   48,345   18,550 
Accrued Expenses  (105,678)  21,764   (177,494)  40,797 
NET CASH USED IN OPERATING ACTIVITIES  (2,737,650)  (1,472,519)  (4,498,579)  (2,695,939)
                
INVESTING ACTIVITIES                
Purchase of Property and Equipment  (23,796)  (41,968)  (33,487)  (55,147)
Purchase of Intangible Assets  (107,124)  (60,147)  (157,922)  (107,152)
Payment Received from Notes Receivable  15,000   632,197   120,522   632,197 
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES  (115,920)  530,082   (70,887)  469,898 
                
FINANCING ACTIVITIES                
Proceeds from issuance of Series B Preferred & Warrants  -   1,000,000   -   1,000,000 
Proceeds from issuance of Series C Preferred & Warrants  -   350,000   -   350,000 
Gross Proceeds from issuance of Common Stock and Warrants  2,521,220   2,040,100   4,981,220   2,040,100 
Less Offering Costs  (326,890)  (443,700)  (655,954)  (443,700)
Dividend on Preferred      (7,486)
Proceeds from exercise of Warrants  75,848   -   75,848   - 
NET CASH PROVIDED BY FINANCING ACTIVITIES  2,270,178   2,946,400   4,401,114   2,938,914 
                
NET CHANGE IN CASH FOR PERIOD  (583,392)  2,003,963   (168,352)  712,873 
                
CASH AT BEGINNING OF PERIOD  1,279,782   1,515,674   1,279,782   1,515,674 
                
CASH AT END OF PERIOD $696,390  $3,519,637  $1,111,430  $2,228,547 
                

Supplemental Disclosures:

            
Noncash investing and financing activities disclosure:                
Conversion of Convertible Debt for Stock $-   (50,000) $-   (50,000)
Common Stock issued for conversion of Series B Preferred  -   1,100 
Common Stock issued for cashless exchange of Warrants  -   5 
Other noncash operating activities disclosure:                
Issuance of Common Stock for services $153,000  $256,264   245,111   223,774 
Disclosure of cash paid for:                
Interest $2,514  $8,761  $2,514  $12,205 
Income Taxes $-  $-  $-  $- 

 

See accompanying notes to condensed financial statements.

5

Sigma Labs, Inc.

Statement of Stockholders’ Equity

(Unaudited)

For the Three and Six Months Ended JuneSeptember 30, 2019 and 2018

  Common Stock       
  Shares Outstanding  Common Stock  Additional Paid-in Capital  Accumulated Deficit  Total 
                
Balances, July 1, 2019  10,937,590  $10,938  $24,243,575  $(22,852,348) $1,402,165 
                     
Shares Sold in Public Offering  3,075,000   3,075   2,127,861       2,130,936 
Shares Issued for Services  25,000   25   92,085       92,110 
Stock Options Awarded to Employees          79,618       79,618 
Net Loss              (1,600,794)  (1,600,794)
Balances, September 30, 2019  14,037,590  $14,038  $26,543,139  $(24,453,142) $2,104,035 

  Common Stock       
  Shares Outstanding  Common Stock  Additional Paid-in Capital  Accumulated Deficit  Total 
                
Balances, July 1, 2018  8,248,729  $8,249  $20,879,827  $(16,760,262) $4,127,814 
                     
Shares Issued for Conversion of Series C Preferred  100,000   100   (100)      - 
Stock Options Awarded to Employees          131,678       131,678 
Net Loss              (1,320,825)  (1,320,825)
Balances, September 30, 2018  8,348,729  $8,349  $21,011,406  $(18,081,087) $2,938,668 

(Unaudited)For the Nine Months Ended September 30, 2019 and 2018

 

   Common Stock         
   Shares Outstanding    Common Stock   AdditionalPaid-in Capital   Accumulated Deficit   Total   
Balances, January 1, 2019  8,776,629  $8,777  $21,501,407  $(19,774,745) $1,735,439 
                     
Net Loss  -   -   -   (1,484,112)  (1,484,112)
Shares sold in Public Offering  1,400,800   1,401   1,677,930   -   1,679,330 
Shares issued for Exercise of Warrants  70,230   70   75,778   -   75,848 
Shares Issued for Cashless Exchange of Unit Purchase Options  88,431   88   (88)  -   - 
Shares Issued for Services  201,500   202   77,798   -   78,000 
Stock Options Awarded to Employees  -   -   176,206   -   176,206 
Balances, March 31, 2019  10,537,590  $10,538  $23,509,031  $(21,258,857) $2,260,711 
 Net Loss  -   -   -   (1,593,491)  (1,593,491)
Shares sold in Private Placement  400,000   400   514,600   -   515,000 
Shares Issued for Services  -   -   75,000   -   75,000 
Stock Options Awarded to Employees  -   -   144,944   -   144,944 
                     
Balances, June 30, 2019  10,937,590   10,938   24,243,575   (22,852,348)  1,402,165 

  Common Stock       
  Shares Outstanding  Common Stock  Additional
Paid-in
Capital
  Accumulated Deficit  Total 
Balances, January 1, 2018  4,978,929  $4,979  $17,192,394  $(14,185,457) $3,011,916 
                     
Net Loss  -   -   -   (1,170,876)  (1,170,876)
Shares Issued for Services  23,256   23   39,977   -   40,000 
Stock Options Awarded to Employees  -   -   140,305   -   140,305 
                     
Balances, March 31, 2018  5,002,185  $5,002  $17,372,676  $(15,356,333) $2,021,345 
Net Loss  -   -   -   (1,388,804)  (1,388,804)
Shares Issued for Services  176,744   177   216,087       216,264 
Convertible Preferred Shares Issued in Private Placement  -   -   877,499   -   877,499 
Shares Issued for Conversion of Series B Preferred  1,000,000   1,000   (1,000)  -   - 
Preferred Dividends Due Upon Conversion  -   -   -   (15,125)  (15,125)
Shares Issued for Notes Payable Conversions  25,000   25   49,975   -   50,000 
Shares Issued for Cashless Exchange of Warrants  4,800   5   (5)  -   - 
                     
Shares Sold in Public Offering  2,040,000   2,040   1,720,360   -   1,722,400 
Series C Convertible Preferred Shares Issued  -   -   346,500   -   346,500 
Stock Options Awarded to Employees  -   -   297,735   -   297,735 
                     
Balances, June 30, 2018  8,248,729   8,249   20,879,827   (16,760,262)  4,127,814 
  Common Stock       
  Shares Outstanding  Common Stock  Additional Paid-in Capital  Accumulated Deficit  Total 
                
Balances, January 1, 2019  8,776,629  $8,777  $21,501,406  $(19,774,745) $1,735,438 
                     
Shares Sold in Public Offerings  4,475,800   4,476   3,805,791   -   3,810,267 
Shares Issued for Exercise of Warrants  70,230   70   75,778   -   75,848 
Shares Issued for Cashless Exchange of Unit Purchase Options  88,431   88   (88)  -   - 
Stock Options Awarded to Employees  -   -   400,768   -   400,768 
Shares Sold in Private Placement  400,000   400   514,600   -   515,000 
Shares Issued for Services  226,500   227   244,884   -   245,110 
Net Loss  -   -   -   (4,678,397)  (4,678,397)
Balances, September 30, 2019  14,037,590  $14,038  $26,543,139  $(24,453,142) $2,104,035 

 

  Common Stock       
  Shares Outstanding  Common Stock  Additional Paid-in Capital  Accumulated Deficit  Total 
                
Balances, January 1, 2018  4,978,929  $4,979  $17,192,394  $(14,185,457) $3,011,916 
                     
Shares Sold in Public Offerings  2,040,000   2,040   1,720,360   -   1,722,400 
Shares Issued for Cashless Exchange of Warrants  4,800   5   (5)  -   - 
Shares Issued for Conversion of Series B Preferred  1,000,000   1,000   (1,000)  -   - 
Shared Issued for Notes Payable Conversions  25,000   25   49,975   -   50,000 
Convertible Preferred Shares Issued in Private Placement  -   -   877,499   -   877,499 
Series C Convertible Preferred Shares Issued  -   -   346,500   -   346,500 
Shares Issued for Conversion of Series C Preferred  100,000   100   (100)  -   - 
Stock Options Awarded to Employees  -   -   569,718   -   569,718 
Shares Issued for Services  200,000   200   256,064   -   256,264 
Preferred Dividends Due Upon Conversion  -   -   -   (15,125)  (15,125)
Net Loss              (3,880,505)  (3,880,505)
Balances, September 30, 2018  8,348,729  $8,349  $21,011,406  $(18,081,087) $2,938,668 

See accompanying notes to condensed financial statements.

6

SIGMA LABS, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

JuneSeptember 30, 2019

(Unaudited)

 

NOTE 1 - Summary of Significant Accounting Policies

 

Nature of Business -Sigma Labs, Inc., formerly named Framewaves, Inc., a Nevada corporation, was founded by a group of scientists, engineers and businessmen to develop and commercialize novel and unique manufacturing and materials technologies. Sigma believes that some of these technologies will fundamentally redefine conventional quality assurance and process control practices by embedding them into the manufacturing processes in real time, enabling process intervention and ultimately leading to closed loop process control. The Company anticipates that its core technologies will allow its clientele to combine advanced manufacturing quality assurance and process control protocols with novel materials to achieve breakthrough product potential in many industries including aerospace, defense, oil and gas, bio-medical, and power generation. The terms the “Company,” “Sigma,” “we,” “us” and “our” refer to Sigma Labs, Inc.

 

Basis of Presentation - The accompanying financial statements have been prepared by the Company in accordance with Generally Accepted Accounting Principles (“GAAP”) in the United States of America. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at JuneSeptember 30, 2019 and 2018 and for the periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted. The Company suggests these condensed financial statements be read in conjunction with the December 31, 2018 audited financial statements and notes thereto included in the Company’s Form 10-K. The results of operations for the periods ended JuneSeptember 30, 2019 and 2018 are not necessarily indicative of the operating results for the full year.

 

Reclassification- Certain amounts in prior-period financial statements have been reclassified for comparative purposes to conform to presentation in the current-period financial statements.

 

Loss Per Share - The computation of loss per share is based on the weighted average number of shares outstanding during the period in accordance with Accounting Standards Codification (“ASC”) Topic No. 260, “Earnings Per Share.” Shares underlying the Company’s outstanding warrants, options or note conversion features were excluded due to the anti-dilutive effect they would have on the computation. At JuneSeptember 30, 2019 the Company had 3,620,610 warrants, 1,108,1921,251,030 stock options and a $50,000 Convertible Note Payable outstanding. The total number of shares of common stock underlying these instruments is 4,753,802.4,896,640. At JuneSeptember 30, 2018 the Company had 350250 convertible preferred stock shares, 3,228,500 warrants, 664,707697,207 stock options and a $50,000 Convertible Note Payable outstanding. The total number of shares of common stock underlying these instruments is 4,268,207.4,200,707.

7

The following data shows the amounts used in computing loss per share and the effect on income and the weighted average number of shares of dilutive potential common stock for the periods ended June 30, 2019 and 2018:

  Three Months Ended June 30  Six Months Ended June 30 
  2019  2018  2019  2018 
             
Net Loss per Common Share - Basic and Diluted $(0.15) $(0.25)  (0.31) $(0.48)
Loss from continuing                
Operations available to Common stockholders (numerator) $(1,593,491) $(1,388,804)  (3,077,603) $(2,559,680)
                 
Weighted average number of common shares Outstanding used in loss per share during the Period (denominator)  10,777,590   5,572,015   10,063,806   5,286,362 

Recently Enacted Accounting Standards - The FASB established the ASC as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in accordance with GAAP. Rules and interpretive releases of the Securities and Exchange Commission (“SEC”) issued under authority of federal securities laws are also sources of GAAP for SEC registrants.

 

In February 2016, the FASB issued ASU 2016-02, “Leases” which was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The amendments in ASU 2016-02 are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company has evaluated this standard and determined that it will not currently require any adjustment to Sigma’s financial reporting.

 

Accounting Estimates - The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated by management. Significant accounting estimates that may materially change in the near future are impairment of long-lived assets, values of stock compensation awards and stock equivalents granted as offering costs, and allowance for bad debts and inventory obsolescence.

 

NOTE 2 - Notes Receivable

 

On May 1, 2017, the Company made a loan in the principal amount of $250,000 to Jaguar Precision Machine, LLC, a New Mexico limited liability company (“Jaguar”), pursuant to a Secured Convertible Promissory Note dated May 1, 2017 delivered by Jaguar to the Company. The loan bears interest at the rate of 7% per annum, was originally due and payable in full on August 1, 2018, is secured by certain assets of Jaguar, and is convertible at the Company’s option into 10% of the outstanding shares of the common stock of Jaguar unless Jaguar exercises its right under specified circumstances to repay all principal and accrued interest on the loan. On June 15, 2018, the Company received a $150,000 payment from Jaguar, $17,803 of which was applied to accumulated interest through that date and $132,197 the balance, of which, was applied to the principal balance of the note. In the first six months of 2019 payments totaling $45,000 were received. The payments were applied first to the accumulated interest balance on the note and then to the remaining principal balance. The holder ofOn September 5, 2019, Jaguar paid the promissory note has committed to paying the remaining principal balance along with accumulatedin full, including accrued interest on or beforethrough September 30, 2019. The June 30, 2019 principal balance of the note was $79,875 and the accumulated interest balance due was $166.

 

NOTE 3 – Inventory

 

At JuneSeptember 30, 2019 and December 31, 2018, the Company’s inventory was comprised of:

 

 June 30, 2019  December 31, 2018  September 30, 2019  December 31, 2018 
Raw Materials $279,835  $168,623  $335,882  $168,623 
Work in Process  265,816   46,688   219,800   46,688 
Finished Goods  24,775   24,775   156,905   24,775 
Total Inventory $570,426  $240,086  $712,587  $240,086 

 

NOTE 4 - Notes Payable

 

At JuneSeptember 30, 2019 and December 31, 2018, the Company had a $50,000 convertible note outstanding due on October 18, 2019. At JuneSeptember 30, 2019 the accumulated interest balance on the note was $1,028.$2,306.

8

NOTE 5 - Stockholders’ Equity

 

Common Stock

 

In January 2018, the Company issued 23,256 shares of common stock to directors valued at $1.72 per share, or $40,000.

 

In April 2018, the Company issued 176,744 shares of common stock to directors valued at $1.22 per share, or $216,264.

 

Between May 29, 2018 and June 1, 2018, we issued an aggregate of 1,000,000 shares of common stock upon conversion of the 1,000 shares of Series B Preferred Stock issued on April 6, 2018 (as described below under “Preferred Stock”).

 

In May 2018 the holder of our Note Payable converted $50,000 of the principal balance of the Note into 25,000 shares of common stock and exercised its warrant on a cashless basis resulting in the issuance of 4,800 shares of common stock.

 

On June 26, 2018, as part of its public offering of equity securities, the Company issued 2,040,000 shares of common stock and warrants to purchase a total of 717,000 shares of common stock (including the warrants described under “Preferred Stock” below that were issued on June 26, 2018). Each warrant has an initial exercise price of $1.08 per share. The net proceeds to the Company were approximately $2,068,900 after commissions and other offering expenses. The Company also issued Dawson James Securities, Inc., its placement agent in the public offering, a Unit Purchase Option to acquire up to 191,200 Units, at an exercise price of $1.25 per Unit, consisting of 191,200 shares of common stock and warrants to purchase up to 57,360 shares of common stock as compensation.

 

In January 2019, the Company issued a total of 200,000 shares of common stock to directors valued at $1.50 per share, or $300,000, with such shares to vest ratably over four quarterly installments, subject in each case to such director’s continuing service as a director.

 

Also in January 2019, the Company issued 88,431 shares of common stock upon the cashless exercise of Unit Purchase Options issued in our June 2018 public offering.

 

In January and February 2019, the Company issued a total of 70,230 shares of common stock upon the exercise of 70,230 warrants having an exercise price of $1.08 resulting in gross cash proceeds of $75,848.

 

In March 2019, the Company issued 1,500 shares of common stock to the Company’s Vice President of Business Development in connection with his achievement of performance milestones, with such shares vesting immediately.

 

Also in March 2019, the Company closed a public offering of equity securities in which it issued 1,400,800 shares of common stock and warrants to purchase a total of 420,240 shares of common stock resulting in net proceeds of approximately $1,679,230, after deducting placement agent commissions and other offering expenses payable by the Company.

 

In May 2019, the Company closed a private placement of equity securities in which it issued 400,000 shares of common stock and warrants to purchase a total of 220,000 shares of common stock resulting in net proceeds of approximately $515,000, after deducting placement agent commissions and other offering expenses payable by the Company.

On August 2, 2019, the Company closed a public offering of equity securities in which it issued 2,875,000 shares of common stock resulting in net proceeds of approximately $1,971,000, after deducting commissions and other offering expenses payable by the Company.

On August 15, 2019, the Company issued 25,000 shares of common stock to MHZCI, LLC, an investor relations firm engaged by the Company, as partial compensation for services to be rendered.

On September 13, 2019, Aegis Capital Corp. partially exercised its over-allotment option granted by the Company in the foregoing August 2019 public offering by purchasing an additional 200,000 shares of common stock, resulting in net proceeds of $148,800 after deducting commissions.

 

Deferred Compensation

 

In previous years and in the sixnine months ended JuneSeptember 30, 2019, the Company issued to various employees, directors, and contractors shares of the Company’s common stock, subject to restrictions, pursuant to the 2013 Equity Incentive Plan (the “2013 Plan”). Such shares were valued at the fair value at the date of issue. The fair value was expensed as compensation over the vesting period and recorded as an increase to stockholders’ equity. During the sixnine months ended JuneSeptember 30, 2019 and JuneSeptember 30, 2018, $153,000$228,000 and $156,875,$213,449 respectively, of the unvested compensation cost related to these issues was recognized.

 

At JuneSeptember 30, 2019, there was $150,000$75,000 of unrecognized deferred compensation expense to be recognized over the remainder of the year.

9

Stock Options

 

In October 2018, at the Annual Meeting of Stockholders of the Company, the Company’s stockholders approved an amendment to the 2013 Plan to increase the number of shares of the Company’s common stock reserved for issuance under the 2013 Plan by 900,000 shares of our common stock to a total of 1,650,000 shares.

In July 2019, at the Annual Meeting of Stockholders of the Company, the Company’s stockholders approved an amendment to the 2013 Plan to increase the number of shares of the Company’s common stock reserved for issuance under the 2013 Plan by 750,000 shares of our common stock to a total of 2,400,000 shares.

In August 2019, the Company terminated its 2011 Equity Incentive Plan.

As of JuneSeptember 30, 2019, an aggregate of 750 shares and 25,460640,122 shares of common stock were reserved for issuance under the 2011 Plan and the 2013 Plan, respectively.Plan.

 

During the sixnine months ended JuneSeptember 30, 2019, the Company granted options to purchase a total of 286,925440,263 shares of common stock to 1821 employees and 1 consultant2 consultants with vesting periods ranging from immediately upon issuance to 4 years beginning January 2019.

 

During the sixnine months ended JuneSeptember 30, 2018, the Company granted options to purchase a total of 374,769404,769 shares of common stock to 1517 employees and 1 consultant with vesting periods ranging from immediately upon issuance to 4 years beginning March 2018.

 

The Company generally grants stock options to employees and directors at exercise prices equal to the fair market value of the Company’s stock on the dates of grant. Stock options are typically granted throughout the year and generally vest over four years of service and expire five years from the date of the award, unless otherwise specified. The Company recognizes compensation expense for the fair value of the stock options over the requisite service period for each stock option award.

 

Total share-based compensation expense included in the consolidated statements of operations for the sixnine months ended JuneSeptember 30, 2019 and 2018 is $474,566$628,768 and $584,589$783,167 of which $321,149$400,768 and $438,039$569,718 is related to stock options, respectively.

 

The fair value of share-based awards was estimated using the Black-Scholes model with the following weighted-average assumptions for the sixnine months ended JuneSeptember 30, 2019 and 2018:

 

Assumptions:

 

  2019  2018 
Dividend yield  0.00   0.00 
Risk-free interest rate  1.90-2.54%  2.68-2.97%
Expected volatility  105.2-106.1%  116.3-137.33%
Expected life (in years)  5   5-10 

10

  2019  2018 
Dividend yield  0.00   0.00 
Risk-free interest rate  1.42-2.53%  2.68-3.05%
Expected volatility  105.2-106.1%  111.4-137.3%
Expected life (in years)  5   5-10 

Option activity for the sixnine months ended JuneSeptember 30, 2019 and the year ended December 31, 2018 was as follows:

 

    Weighted Average Weighted Average        Weighted Average Weighted Average    
    Exercise Remaining Aggregate     Exercise Remaining Aggregate 
    Price Contractual Intrinsic     Price Contractual Intrinsic 
 Options ($) Life (Yrs.) Value ($)  Options  ($)  Life (Yrs.)  Value ($) 
Options outstanding at December 31, 2017  299,938   4.40   7.33      299,938   4.57   7.33     
Granted  534,329   1.45   6.58      534,329   1.45   6.58     
Exercised  -   -   -      -   -   -     
Forfeited or cancelled  (8,000)  4.59   -      (8,000)  4.59   -     
Options outstanding at December 31, 2018  826,267   2.49   6.47      826,267   2.49   6.47     
Granted  286,925   1.55   4.63      440,263   1.46   4.89     
Exercised  -   -   -      -   -   -     
Forfeited or cancelled  (5,000)  1.15   -      (15,500)  1.76   -     
Options outstanding June 30, 2019  1,108,192   2.25   5.61   45,830 
Options expected to vest in the future as of June 30, 2019  388,858   2.22   5.48   28,309 
Options exercisable at June 30, 2019  719,334   2.28   5.69   17,521 
Options vested, exercisable, and options expected to vest at June 30, 2019  1,108,192   2.25   5.61   45,830 
Options outstanding September 30, 2019  1,251,030   2.14   5.41     - 
Options expected to vest in the future as of September 30, 2019  446,582   1.66   5.07   - 
Options exercisable at September 30, 2019  804,448   2.40   5.61   - 
Options vested, exercisable, and options expected to vest at September 30, 2019  1,251,030   2.14   5.41   - 

 

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of our common stock for those awards that have an exercise price currently below the $1.40$0.70 closing price of our common stock on JuneSeptember 30, 2019. 22,916None of the 2019 option grants have an exercise price currently below $1.40.$0.70.

 

At JuneSeptember 30, 2019, there was $348,220$399,258 of unrecognized share-based compensation expense related to unvested share options with a weighted average remaining recognition period of 3.023.09 years.

 

Warrants

 

Warrant activity for the sixnine months ended JuneSeptember 30, 2019 and 2018 was as follows:

 

    Weighted Average Weighted Average     Weighted
Average
 Weighted Average 
    Exercise Remaining     Exercise Remaining 
    Price Contractual     Price Contractual 
 Warrants  ($) Life (Yrs.)  Warrants  ($)  Life (Yrs.) 
Warrants outstanding at December 31, 2017  1,645,500   3.97   4.11   1,645,500   3.97   4.11 
Granted  1,607,000   1.30   4.64   1,607,000   1.30   4.64 
Exercised  (24,000)  2.00   -   (24,000)  2.00   - 
Forfeited or cancelled  -   -   -   -   -   - 
Options outstanding at June 30, 2018  3,228,500   2.65   4.40 
Warrants outstanding at September 30, 2018  3,228,500   2.65   4.14 
                        
Options outstanding at December 31, 2018  3,050,600   2.75   3.86 
Warrants outstanding at December 31, 2018  3,050,600   2.75   3.86 
Granted  640,240   1.60   4.94   640,240   1.60   4.68 
Exercised  (70,230)  1.08   -   (70,230)  1.08   - 
Forfeited or cancelled  -   -   -   -   -   - 
Options outstanding at June 30, 2019  3,620,610   2.58   3.63 
Warrants outstanding at September 30, 2019  3,620,610   2.58   3.37 

 

NOTE 6 - Subsequent Events

 

In July and August ofOn October 11, 2019, the Company granted our CEO and President two optionsits Chief Technology Officer an option to purchase up to 22,916 and 22,92250,000 shares of our common stock respectively under ourthe Company’s 2013 Equity Incentive Plan in connection with his employment arrangement.Plan. The options haveoption has an exercise price per share equal to $1.40$0.67 and $0.74, respectively, and each is fully vested.

 

In July ofOn October 18, 2019, at the Annual Meeting of Stockholders of the Company, the Company’s stockholders approved an amendment to the 2013 Equity Incentive Plan to increase the number of sharesmaturity date of the Company’s common stock reserved for issuance under the 2013 Plan by 750,000 shares of our common stockoutstanding $50,000 convertible promissory note was extended to a total of 2,400,000 shares.

In July of 2019, the Company granted options to purchase a total of 97,500 shares of common stock to 7 employees and 1 consultant with vesting periods ranging from immediately upon issuance to 4 years beginning JulyJanuary 3, 2020.

In August of 2019, the Company closed a public offering of equity securities in which it issued 2,875,000 shares of common stock resulting in net proceeds of approximately $1,971,000, after deducting placement agent commissions and other offering expenses payable by the Company.

11

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Forward-looking statements

 

This Quarterly Report, including any documents which may be incorporated by reference into this Report, contains “Forward-Looking Statements.” All statements other than statements of historical fact are “Forward-Looking Statements” for purposes of these provisions, including any projections of revenue or other financial items, any statements of the plans and objectives of management for future operations, any statements concerning proposed new products or services, any statements regarding future economic conditions or performance, and any statements of assumptions underlying any of the foregoing. All Forward-Looking Statements included in this document are made as of the date hereof and are based on information available to us as of such date. We assume no obligation to update any Forward-Looking Statement. In some cases, Forward-Looking Statements can be identified by the use of terminology such as “may,” “will,” “expects,” “plans,” “anticipates,” “intends,” “believes,” “estimates,” “potential,” or “continue,” or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the Forward-Looking Statements contained herein are reasonable, there can be no assurance that such expectations or any of the Forward-Looking Statements will prove to be correct, and actual results could differ materially from those projected or assumed in the Forward-Looking Statements. Future financial condition and results of operations, as well as any Forward-Looking Statements are subject to inherent risks and uncertainties, including any other factors referred to in our press releases and reports filed with the Securities and Exchange Commission (“SEC”). All subsequent Forward-Looking Statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Additional factors that may have a direct bearing on our operating results are described under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018 and elsewhere in this report.

 

Corporation Information

 

Our principal executive offices are located at 3900 Paseo del Sol, Santa Fe, New Mexico 87507, and our telephone number is (505) 438-2576. Our website address iswww.sigmalabsinc.com. The Company’s annual reports, quarterly reports, current reports on Form 8-K and amendments to such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”), and other information related to the Company, are available, free of charge, on that website as soon as we electronically file those documents with, or otherwise furnish them to, the SEC. The Company’s website and the information contained therein, or connected thereto, are not and are not intended to be incorporated into this Quarterly Report on Form 10-Q.

 

2019 RTE Developments

 

Sigma entered 2019 six weeks after releasing the commercial industrial model of its technology, PrintRite3D® 4.0, wrapped in a strategy called the Rapid Test and Evaluation Program (“RTE”) to take the product to market. The RTE is a ‘drive before you buy’ approach that is aimed only at companies that meet four criteria: (1) the company must be a large recognized brand; (2) the company must be either an end-user manufacturing or buying Additive Manufacturing (AM) metal parts requiring the capacity of 20 or more AM metal machines, or the target company must be an Original Equipment Manufacturer (“OEM”) with a well-recognized brand and a significant AM metal manufacturing growth initiative in process; (3) the company must have substantial concern about the quality yields and risks of its AM metal production; and (4) the company must be willing to stipulate what PrintRite3D® 4.0 would have to prove in order to meet the company’s quality improvement and sustainability goals. Sigma Labs asserted that the way to measure RTEs in 2019 would be the number and quality of the companies that contracted with Sigma in the program, rather than the immediate revenue from the program, because ‘drive before you buy’ causes revenue to be back-end loaded.

In the first quarter of 2019, Sigma determined what would become a norm in the RTE requirement for the target companies: they would install PrintRite3D® on one of their laser powderbed AM machines and if the results were confirmed by a third party laboratory to meet their written quality needs, they would then ask Sigma to install a Phase 2 on one or two additional machines of different manufacturers than the first in order to determine if PrintRite3D® works equally effectively on multiple OEM brands, as well as multiple machines of the same brand, and finally on multiple laser machines as well. This unexpected customer enhancement to the scope of the RTE program raised the revenue potential that ultimately may be derived from the conversion of a single unit test run into a permanent license sale from a single unit followed by 2 or 3 (simultaneously) in Phase 2. This potential expansion of RTE scope commensurately increased the duration of some RTEs due to the serial nature of testing first on one machine, followed by a Phase 2 validation on multiple machines. There is a perceptible customer learning curve factor on RTEs, and we expect Phase 2 testing to benefit from this Phase 1 learning curve and be much more rapid than Phase 1 tests.

Through the end of the third quarter, the RTE results are favorable. A leading global energy technology company for whom on-site testing began in April 2019, has ordered a Phase 2 and as stated in our November 13, 2019 press release, this is the final phase ahead of a potentially broader global rollout of the technology to their additive manufacturing machine base. The major service provider, with whom on-site testing began in March 2019, has also now begun its second RTE to start on a different OEM brand from the first RTE tests. The major OEM whose purchase order for an RTE we announced in August 2019 has only its own brand and has agreed to complete two simultaneous test units on different models and is thus on a fast track. Airbus is developing on schedule and expects to require a Phase 2 if and after the current RTE meets their needs. Materialise, a diverse AM company and an OEM for AM control systems and software, was a Sigma alpha test of the RTE program and with whom we announced in June 2019 that Sigma had entered into a non-binding Memorandum of Understanding to integrate PrintRite3D® with Materialise’s new MPC AM equipment control system. As noted below, we recently announced that Materialise has invited Sigma’s Chief Technology Officer to deliver two lectures in November 2019 in Materialise’s booth at FormNext on “Integration of PrintRite3D Melt Pool Monitoring Software with Materialise’s MPC Machine Control System for Advanced Process Control.”

Additionally, commencing in June 2019, Sigma opened a third channel to market. With the release of PrintRite3D® 5.0, Sigma brought a user-friendly version of its product to market that no longer requires substantial onsite customer support from Sigma. Therefore, the Company commenced calling on research tanks, universities, and small users to open a ‘retail’ channel.

Other Recent Developments

On November 7, 2019, we reported several events, includingannounced that we will demonstrate the following (in reverse chronological order):latest version of our proprietary PrintRite3D®Real-Time Melt Pool Analytics software platform in conjunction with Materialise NV at the Formnext 2019 conference in Frankfurt, Germany, on November 19-22, 2019. Materialise has invited our Chief Technology Officer to present on “Integration of PrintRite3D Melt Pool Monitoring Software with Materialise’s Machine Control Platform (MCP) for Advanced Process Control” at Materialise’s booth in Hall 12.1, Booth C131.

On November 5, 2019, we announced that we have partnered with a Japanese high-end manufacturer of state-of-the-art machine tools, electrical discharge machines (EDM) and 3D printing products, for a test and evaluation program of Sigma Labs’ PrintRite3D® real time melt pool analytics.

On October 23, 2019, we announced that we have been awarded a contract by VTT Technical Research Centre of Finland Ltd, an impartial, state-owned non-profit research and technology organization with the mission to support economic competitiveness, societal development and innovation in Finland, to install our proprietary PrintRite3D® Real-Time Melt Pool Analytics software platform at the VTT 3D metal printing facility.

 

On August 13, 2019, we announced that we have been selected by a major international OEM machine manufacturer to install our proprietary PrintRite3D® products. As part of the agreement, the OEM will complete our Rapid Test and Evaluation program and will install the PrintRite3D® in two different countries for analysis and proof-of-performance purposes.

 

On August 2, 2019, we closed a public offering of equity securities in which we issued 2,875,000 shares of common stock resulting in net proceeds of approximately $1,971,000, after deducting placement agent commissions and other offering expenses payable by us.

 

On July 30,1, 2019, we announced that we will work with Airbus to complete a Testappointed experienced financial executive and Evaluation Program ofproven business leader Frank Orzechowski as our new PrintRite3D® version 5.0 hardware and software followed by a validation phase on a powderbed fusion printer.

On June 18, 2019, we announced that we signed a non-binding Memorandum of Understanding with Materialise NV to cooperate in the integration of their MCP Controller with our PrintRite3D® technology. Combining the sophisticated control technology with in-situ process monitoring for metal additive manufacturing will give customers maximal control on the production process, allowing them to become even more productive.

On May 14, 2019, we announced that we will launch Version 5.0 of our PrintRite3D® platform at the RAPID+TCT 2019 Additive Manufacturing Conference in Detroit on May 21-23, 2019.

On April 30, 2019, we announced that the Company’s PrintRite3D® software has been shown to ensure process consistency and product quality in metal additive manufacturing, according to a research study sponsored by the Defense Advanced Research Project Agency (DARPA) Open Manufacturing Program and conducted in tandem with Honeywell Aerospace at Honeywell’s Advanced Manufacturing Engineering Center. The paper, titled “LPBF [Laser Powder Bed Fusion] Right the First Time-the Right Mix Between Modeling and Experiments,” discusses the validation involved in manufacturing a challenging metal component.

12

On March 26, 2019, we announced the appointment of the Company’s new Business Development Manager, Americas, who will be responsible for developing key accounts through the Company’s Rapid Test and Evaluation Program and for bringing PrintRite3D INSPECT® into deployment across serial production operations in North and South America.

On March 15, 2019, we closed a public offering of equity securities resulting in net proceeds of approximately $1,679,230, after deducting placement agent commissions and other offering expenses payable by us.

On February 26, 2019, we announced that we were named a member of the Manufacturing Technology Centre (“MTC”) located at Ansty Park, Coventry, UK. Being a member of the MTC enables us to share and provide expertise and solutions for a number of MTC’s projects and also network with MTC’s existing members, including some of the UK’s leading aerospace companies.

On February 12, 2019, we announced that we were named a member of the Additive Alliance of Fraunhofer IAPT, a leading network for additive manufacturing (“AM”). As the first US company to be granted a membership in the Alliance, Sigma became part of the global research consortium to advance the development and implementation of AM. The membership enables us to demonstrate our PrintRite3D® technology to key players in the market of metal AM.

On February 5, 2019, we announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/276,452, “Optical Manufacturing Process Sensing and Status Indication System.” The patent application covers a system of sensors configured to measure optical emissions generated by a scanning heat source during an additive manufacturing (AM) process and to analyze the data collected.

On January 17, 2019, we announced we were awarded a Test and Evaluation Program contract with a leading global materials and service provider in AM. The program is designed to demonstrate the value of Sigma’s PrintRite3D® product capabilities and performance and to validate and quantify the repeatability and variability of AM production processes. So far we have had delays, diversions, and logistical alterations typical of many newly launched programs, yet importantly, there have been no negative performance issues in the RTE test results. The prototype RTE installation was with Materialise in 2018 and culminated in the project announced in June 2019 to integrate Sigma’s technology with Materialise’s MCP control system. As of the date of this Quarterly Report, of our two most advanced RTEs in process, one states an expectation to add a second PrintRite3D® installation, and the other expects to enter the phase two evaluation (multiple machines of differing OEM brands) over the next 60-120 days.

The size and quality of the demanding high technology ‘brand name’ companies currently participating in, along with those teed-up to enter the RTE program, appears to confirm that the program is Sigma’s most auspicious highway to success and material revenue driving into 2020 and beyond. The Airbus RTE announcement on July 30, 2019 followed by our OEM double-RTE announcement on August 13, 2019 demonstrates that the market’s uptake of this program initiative is accelerating.Chief Financial Officer.

 

Critical Accounting Policies

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts in the accompanying consolidated financial statements and related notes. These estimates and assumptions have a significant impact on our consolidated financial statements. Actual results could differ materially from those estimates. Critical accounting policies are those that require the most subjective and complex judgments, often employing the use of estimates about the effect of matters that are inherently uncertain. Our significant accounting policies are disclosed in Note 1 to the Financial Statements included in this Quarterly Report on Form 10-Q. However, we do not believe that there are any alternative methods of accounting for our operations that would have a material effect on our financial statements.

 

Results of Operations

 

Three Months Ended June 30, 2019 and June 30, 2018

We expect to generate revenue primarily by selling and licensing our IPQA technologies, selling technical support services, contract manufacturing and selling specialty parts and studies to businesses that seek to improve their manufacturing production processes and production-run quality yields. Our ability to generate revenues in the future will depend on our ability to further commercialize and increase market presence of our PrintRite3D® technologies, and it will depend on whether key prospective customers continue to move from AM metal prototyping to production.

Three Months Ended September 30, 2019 and September 30, 2018

 

During the three months ended JuneSeptember 30, 2019, we recognized revenue of $33,582,$171,003 as compared to $98,663$128,593 in revenue recognized during the same period in 2018, a reductionan increase of $65,081. $10,000 of the reduction$42,410. The increase is directly attributable to the commercial sale of a PrintRite3D® unit in the third quarter, partially offset by the absence of any government program work in 2019, while the remaining 55,000 of it is attributableas well as a decline in AM revenue due to the 100% dedication of our printer to Internalinternal R&D in the second quarter of 2019 as we acceleratedcontinued development of the Inspect product, as well as an overall decline in AM revenue.our PrintRite3D® product.

 

Our Costcost of Revenuerevenue for the three months ended JuneSeptember 30, 2019 and 2018 was $60,625$178,760 and $68,568,$56,309, respectively, a reductionan increase of $7,943.$122,451. The decrease in our gross marginincrease is primarily attributable to the sale of a PrintRite3D® unit, a write-off of obsolete inventory of $9,360, expensing of small, low cost inventory items totaling $16,029, and the remainder due to the additional travel and labor costs associated with the on-site and remote collaboration involved in initiationthe growth of the Company’s Rapid Test and Evaluation programs.

13

program.

Sigma’s total operating expenses for the three months ended JuneSeptember 30, 2019 were $1,569,064$1,600,914 as compared to $1,422,511$1,401,087 for the same period in 2018, an increase of $146,553.$199,827.

 

The most significant of our operating costs are personnel costs, comprised of payroll, benefits, and stock-based compensation expense. Together these costs totaled 50% of our operating expenses for the third quarter. Salary and benefits costs were $581,356$644,800 for the three months ended JuneSeptember 30, 2019 compared to $426,049$524,508 for the same period in 2018, an increase of $155,307.$120,292. This 36%23% cost increase correlates to a net increase of five full-time equivalent employees between the two periods which is a 31% increase in employee count.

 

Stock-based compensation was $220,360$154,202 for the three months ended JuneSeptember 30, 2019 compared to $423,067$198,578 for the same period in 2018, a $202,707,$44,376, or 48%22%, decrease, primarily due to 2018 secondthird quarter vesting of options granted to our former CEO in connection with his amended employment agreement.

 

Research and development expenditures of $118,845$212,230 were incurred during the three months ended JuneSeptember 30, 2019 compared to $95,049$139,090 in the same period of 2018, a 25%53% increase. The increase primarily results from the purchase of upgraded PrintRite3D® components and various pieces of specialized equipment as part of our continued acceleration of technology development.

 

Public company costs and investor relation fees incurred in the third quarter of 2019 were $194,130, compared to $142,821 incurred during the same period in 2018, primarily due to increased costs associated with our 2019 annual shareholders’ meeting of $14,080, common shares issued as additional fees to our new investor relations firm totaling $17,110, and increased expenses related to website enhancements of $12,024.

Outside professional services fees incurred in the three months ended JuneSeptember 30, 2019 were $218,919$116,221 compared to $177,929$185,676 incurred during the same period in 2018, a 23% increase.37% decrease. The increasedecrease is primarily attributable to recruiting feeslower utilization of outside legal counsel and outside recruiters, and expenses incurred in 2018 for senior employees.European CE certification for our PrintRite3D®units.

 

Office expenses incurred during the three months ended JuneSeptember 30, 2019 were $184,068$186,430 compared to $110,936$131,629 incurred during the same period in 2018, an increase of $73,132,$54,801, or 66%42%. The increase is primarily due to increased travelamortization of costs related to our membership in the UK’s National Center for Additive Manufacturing (“NCAM”) of $59,936,$39,000 and other miscellaneous office expenses of $13,196.$14,740.

 

Sigma’s net loss for the three months ended JuneSeptember 30, 2019 totaled $1,593,491$1,600,794 as compared to $1,388,804$1,320,825 for the same period of 2018, a $204,687$279,969 increase. The reduction in gross profit contributed $57,138$80,041 to the increased loss, while increased operating expenses contributed $146,553$199,827 to the increased loss.

 

SixNine Months Ended JuneSeptember 30, 2019 and 2018

 

During the sixnine months ended JuneSeptember 30, 2019, we recognized revenue of $98,032$269,035 compared to $202,078$330,671 during the same period of 2018. The primary contributors to the $104,046$61,636 reduction were revenue decreases of $32,300 from the absence of any government work, $63,000 is attributablea decline in AM revenue due to the 100% dedication of our printer to Internalinternal R&D in 2019, and the balance from an overall decline in AM revenue.commercial unit sales and annual maintenance programs,

 

Our cost of revenue for the sixnine months ended JuneSeptember 30, 2019 was $157,180$335,939 compared to $142,363$198,672 during the same period in 2018. The increase of $14,817$137,267 is primarily due to the sale of a PrintRite3D® unit, a write-off of obsolete inventory of $9,360, expensing of small, low cost inventory items totaling $16,029, and the remainder due to additional travel and labor costs associated with the on-site and remote collaboration involved in initiation of the Company’s Rapid Test and Evaluation programs.program.

 

Sigma’s total operating expenses for the sixnine months ended JuneSeptember 30, 2019 were $3,076,162$4,677,077 compared to $2,599,641$4,000,728 for the same period in 2018, a $476,521$676,349 increase.

 

Payroll costs for the sixnine months ended JuneSeptember 30, 2019 were $1,093,916$1,738,716 compared to $824,706$1,349,214 for the same period in 2018. The $269,210 increases result$389,502 increase results primarily from the earlier mentioned addition of five employees since the end of the second quarter of 2018. Stock-based compensation for the sixnine months ended JuneSeptember 30, 2019 was $474,566$628,768 compared to $584,589$783,167 for the same period in 2018, a $110,023$154,399 decrease, primarily due to the vesting of options granted to our former CEO in connection with his amended employment agreement in 2018.

 

During the sixnine months ended JuneSeptember 30, 2019, Sigma incurred research and development expenditures of $264,177$476,346 compared to $217,022$356,112 in the same period of 2018. The $47,155$120,234 increase in these expenditures during the first sixnine months of 2019 resulted primarily from the purchase of upgraded servers and various pieces of specialized equipment as part of our continued acceleration of technology development, as well as $35,333 of consulting fees paid in connection with the development of Version 5.0 of our PrintRite3D®platform.

 

Sigma’s public company and investor relation fees incurred in the sixnine months ended JuneSeptember 30, 2019 were $315,107,$509,237, compared to $283,596$426,417 during the same period in 2018. The $31,511 increase in the six-monthnine-month comparative expenditures results primarily from shares of common stock issues to our new investor relations firm of $17,110 and an increase in advertising expenses of $64,600, partially offset by a decrease$74,939, due to enhancements to marketing programs and materials, website redesign and upgrades, and advertisements in shareholder services expenses of $37,100.trade publications.

 

Outside services fees incurred in the sixnine months ended JuneSeptember 30, 2019 were $403,489,$519,710, compared to $316,352$502,028 incurred during the same period in 2018, a 28%4% increase. ConsultingAccounting and audit fees increased $22,366, consulting fees increased by $67,552$40,785 due to the addition of an application engineer consultant, and recruitingwhile legal fees increaseddecreased by $19,428.

14

$34,443.

During the sixnine months ended JuneSeptember 30, 2019, Sigma’s office expenses were $350,178$536,608 compared to $206,042$337,671 in the same period of 2018. The $144,136$198,937 increase in these expenditures primarily resulted from amortization of our prepaid three year membership in the UK’s National Center for Additive Manufacturing (“NCAM”) of $39,000, rent & utilities of $15,164, and additional travel expenseexpenses of $90,814 related to both a more aggressive outreach to prospective OEM, service bureau and end user customers, and our expansion into the European market.and Asian markets. Other miscellaneous office expenses, consisting of computer hardware, software, and office supplies increased $36,254 over the same period in 2018.

 

In the sixnine months ended JuneSeptember 30, 2019, our net other income & expense was net income of $57,707,$65,584, as compared to net expense of $19,754$11,776 during the same period in 2018. The six-monthnine-month 2019 net other income is primarily comprised of $52,000$17,610 of interest income and $51,877 in New Mexico state job incentive credits received. The net other expense for the same period in 2018 is primarily due to a $36,733 write-off of accounting software, partially offset by interest income of $17,086$26,948 on the then outstanding notes receivable.

 

Sigma’s net loss for the sixnine months ended JuneSeptember 30, 2019 totaled $3,077,603$4,678,397 as compared to $2,559,680$3,880,505 for the same period in 2018, a $517,923$797,892 increase. Contributing to this increase was an increase in our operating loss of $595,384, consisting of a decrease in gross profit of $118,863,$198,903 together with an increase in operating expenses of $476,521.$676,349. This was partially offset by an increase in other income and expense of $77,461.$77,360.

 

We financed our operations during the three and sixnine months ended JuneSeptember 30, 2019 and 2018 primarily from revenue generated from PrintRite3D® system sales and engineering consulting services we provided to third parties during these periods and through sales of our common and preferred stock. We expect that our revenue will increase in future periods as we seek to further commercialize and expand our market presence for our PrintRite3D®-related technologies and obtain new contract manufacturing orders in connection with our EOS M290.

 

Liquidity and Capital Resources

 

As of JuneSeptember 30, 2019, we had $696,390$1,111,430 in cash and working capital of $685,409,$1,379,426 as compared with $1,279,782 in cash and working capital of $1,052,017 as of December 31, 2018.

 

Our major sources of funding have been proceeds from public and private offerings of our equity securities (both common stock and preferred stock), and from warrant exercises.

 

In March 2019, the Company closed a public offering of equity securities in which it issued 1,400,800 shares of common stock and warrants to purchase a total of 420,240 shares of common stock resulting in net proceeds of approximately $1,679,330, after deducting placement agent commissions and other offering expenses payable by the Company.

 

In May 2019, the Company closed a private placement of equity securities in which it issued 400,000 shares of common stock and warrants to purchase a total of 220,000 shares of common stock resulting in net proceeds of approximately $515,000, after deducting placement agent commissions and other offering expenses payable by the Company.

 

In August 2019, the Company closed a public offering of equity securities in which it issued 2,875,000 shares of common stock resulting in net proceeds of approximately $1,971,000, after deducting placement agent commissions and other offering expenses payable by the Company.

 

In September 2019, Aegis Capital Corp. partially exercised its over-allotment option granted by the Company in the foregoing August 2019 public offering by purchasing an additional 200,000 shares of common stock, resulting in net proceeds of $148,800 after deducting placement agent commissions.

During the remainder of 2019, we expect to sustain our operations and our commercialization and marketing efforts without a material increase in our cash burn rate. We expect that enhancements of our IPQA®-enabled PrintRite3D® technology that were developed substantially in fiscal 2018 and 2019 and brought to market will enable us to further commercialize this technology for the AM metal market in 2019 and beyond. However, until commercialization of our full suite of PrintRite3D® technologies, we plan to continue funding our development activities and operating expenses by licensing our PrintRite3D® systems and supporting field services, as applicable, and providing PrintRite3D®-enabled engineering consulting services concerning our areas of expertise (materials and manufacturing quality assurance and process control technologies) and contract manufacturing for metal AM, and through the use of proceeds from sales of our securities.

 

Net Cash Used in Operating Activities

 

Net cash used in operating activities during the sixnine months ended JuneSeptember 30, 2019 increased to $2,737,650$4,498,579 from $1,472,519$2,695,939 during the same period in 2018, a $1,265,131$1,802,640 increase. Increased net loss contributed $517,923$797,892 toward this use of cash, increased inventory purchases contributed $377,440$451,221 as a result of our finished goods ramp program, increased prepaid expenses contributed $153,705, and a net decrease of accounts payable and accrued expenses contributed $164,370.$218,291.

 

Net Cash Used/Provided by Investing Activities

 

Net cash used by investing activities during the sixnine months ended JuneSeptember 30, 2019 was $115,920,$70,887, which compares to $530,082$469,898 of cash provided by investing activities during the same period of 2018, a decrease of $646,002.$540,785. This is primarily attributable to the March 2018 receipt of payment in full of a then outstanding $500,000 loan receivable.

15

Net Cash Used/Provided by Financing Activities

 

Cash provided by financing activities during the sixnine months ended JuneSeptember 30, 2019 decreasedincreased to $2,270,178$4,401,114 from $2,946,400$2,938,914 during the same period in 2018 due to lowerincreased proceeds from our public and private securities offerings in 2019.

 

The Company anticipates continued losses in 2019, with any expected increased revenues offset by increased salaries and related expenses in connection with additional employees.

 

We have no credit lines as of AugustNovember 14, 2019, nor have we ever had a credit line since our inception.

 

Based on the funds we have as of AugustNovember 14, 2019, and the proceeds we expect to receive from rapid test and evaluation engagements for our updated PrintRite3D® hardware and software technology, sales of contract AM manufacturing for metal AM parts, and from possible sales of our securities, and from the repayment of loans made by Sigma, we believe that we will have sufficient funds to pay our administrative and other operating expenses through 2019. Our ability to continue to fund our liquidity and working capital needs will be dependent upon the success of and revenues from existing and future PrintRite3D®-proof of concept contracts, follow-on contracts resulting from successful proof of concept engagements, possible strategic partnerships, contract manufacturing orders in connection with our EOS M290, and possibly by obtaining additional capital from the sale of securities or by borrowing funds from lenders to fulfill our business plans. If we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. There is no assurance that we will be successful in obtaining additional funding. If we require and fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our commercialization efforts and operations.

 

We have no off-balance sheet arrangements as defined in Item 303(a) of Regulation S-K.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of disclosure controls and procedures and changes in internal controls over financial reporting.

 

Rule 13a-15(e) under the Exchange Act defines the term “disclosure controls and procedures” as those controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Based upon an evaluation of the effectiveness of our disclosure controls and procedures performed by our management, with the participation of our Chief Executive Officer, and our Principal Financial and Accounting Officer, as of the end of the period covered by this quarterly report, our management concluded that our disclosure controls and procedures are effective at a reasonable assurance level in ensuring that information required to be disclosed by us in our reports is recorded, processed, summarized and reported within the required time periods. In addition, no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) occurred during the three months ended JuneSeptember 30, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

16

PART II

 

OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

Not applicable.

 

ITEM 1A. RISK FACTORS.

 

Not applicable.You should consider the “Risk Factors” included under Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on April 1, 2019. Except for the below, there have been no material changes to those Risk Factors.

There is no assurance that we will satisfy or regain compliance with the continued listing requirements of The NASDAQ Capital Market.

We cannot assure you that we will be able to satisfy or regain compliance with the continued listing requirements of The Nasdaq Capital Market. For example, there is no assurance that our common stock will have a bid price of at least $1.00 per share, which is the minimum bid price under such continued listing requirements, or that we will be able to satisfy other quantitative continued listing requirements, including the minimum stockholders’ equity requirement of at least $2,500,000 for continued listing on The Nasdaq Capital Market. On April 8, 2019, Nasdaq notified us that we did not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). In our Form 8-K filed on September 4, 2019, we disclosed that we had regained compliance with such rule as a result of our August 2019 underwritten public offering. On October 8, 2019, we received a letter from Nasdaq notifying us that, as a result of such offering, Nasdaq determined that we were in compliance with the minimum $2,500,000 stockholders’ equity requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1), but that if we do not demonstrate continued compliance with such rule as of December 31, 2019, the Company’s common stock may be subject to delisting. The Company is evaluating various courses of action to demonstrate compliance. However, there can be no assurance that we will be able to demonstrate compliance. If we do not demonstrate compliance, and there is no assurance that Nasdaq would accept a plan to regain compliance, Nasdaq could provide notice that our common stock will become subject to delisting. In such event, Nasdaq rules would permit us to appeal the decision to reject our proposed compliance plan, if applicable, or any delisting determination to a Nasdaq Hearings Panel. If our securities are de-listed from The Nasdaq Capital Market, our stockholders could incur material adverse consequences such as reduced liquidity for their securities and reduced market prices for their securities. Following such de-listing, we could encounter increased difficulty in issuing additional securities at an attractive price, or at all, in order to fund our operations.

Additionally, as previously disclosed, on September 12, 2019, we received notice from Nasdaq that the closing bid price for our common stock had been below $1.00 per share for the last 30 consecutive business days, and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notice indicates that the Company has 180 calendar days, or until March 10, 2020, to regain compliance with this requirement. We can regain compliance with the $1.00 minimum bid price requirement if the closing bid price of the Company’s common stock is at least $1.00 for a minimum of ten consecutive business days during the 180-day compliance period. If the Company does not regain compliance during the initial compliance period, the Company may be eligible for additional time to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, except the bid price requirement, and will need to provide written notice to Nasdaq of the Company’s intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Company meets these requirements, we expect that Nasdaq will grant the Company the additional 180 calendar days to regain compliance with the minimum bid price requirement. If it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will notify us that the Company’s common stock will be subject to delisting.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

On May 7,August 15, 2019, wethe Company issued to an accredited investor 400,00025,000 shares of common stock and warrants to purchase a total of 200,000 shares of common stock. We also Sigma issuedMHZCI, LLC, an investor relations firm engaged by the Company, as partial compensation for services to Dawson James Securities, Inc., our placement agent in the foregoing private placement, warrants to purchase up to 20,000 shares of common stock, as compensation.be rendered. The foregoing securities were issued in reliance upon an exemption from the registration requirements pursuant to Section 4(2) of the Securities Act.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

Not applicable.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

None.

 

ITEM 6. EXHIBITS.

 

1.1

Underwriting Agreement, dated July 30, 2019, by and among Sigma Labs, Inc. and Aegis Capital Corp. acting as the representative of the several underwriters named on Schedule I thereto (filed as Exhibit 1.1 to the Company’s Current Report on Form 8-K filed August 1, 2019, and incorporated herein by reference).

4.1Form of Common Stock Purchase Warrant.(filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed May 8, 2019, and incorporated herein by reference).
4.2

Form of Placement Agent Warrant (filed as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed May 8, 2019, and incorporated herein by reference).

10.1Securities Purchase Agreement, dated as of May 7, 2019, between the Company and the Purchaser (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 8, 2019, and incorporated herein by reference).
  
10.2Employment letter agreement, effective as of July 1, 2019, between the Company and Frank D. Orzechowski.* **
10.32013 Equity Incentive Plan, (filed as amended, of Sigma Labs, Inc. (previously filed by the Company as Annex AExhibit 10.2 to the Company’s Definitive Proxy StatementQuarterly Report on Schedule 14AForm 10-Q filed on June 18,August 14, 2019, and incorporated herein by reference).*
  
31.1Rule 13a-14(a) Certification of Principal Executive Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.** **
  
31.2Rule 13a-14(a) Certification of Principal Financial Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.** **
  
32.1Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.** ***
  
101.INSXBRL Instance Document.
101.SCHXBRL Schema Document.
101.CALXBRL Calculation Linkbase Document.
101.DEFXBRL Definition Linkbase Document.
101.LABXBRL Labels Linkbase Document.
101.PREXBRL Presentation Linkbase Document.

 

* Indicates a management contract or compensatory plan or arrangement.

** Filed herewith.

*** Furnished herewith and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

17

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 SIGMA LABS, INC.
   
AugustNovember 14, 2019By:/s/ John Rice
  John Rice
  Chairman of the Board, President and Chief Executive Officer (Principal Executive Officer)
   
AugustNovember 14, 2019By:/s/ Frank Orzechowski
  Frank Orzechowski
  Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)

18